Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EMMAUS LIFE SCIENCES, INC.NONE · Entity 156030 | Director · Chairman and CEO · 10% owner | July 09, 2019 | July 11, 2019 |
| Emmaus Life Sciences, Inc.EMMA · Entity 205 | Director · Chairman and CEO · 10% owner | January 12, 2023 | January 17, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EMMAUS LIFE SCIENCES, INC.
Report date July 09, 2019 · Filed July 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Promissory Note dated 9/14/17, as amendedSEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2019-07-31 | Direct | 1 |
Reported balance
After 2019-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-09 · Other · Acquired 1 · Balance 1 F1: The outstanding promissory note of the Issuer held by the Reporting Person was amended to provide for the automatic conversion of the outstanding principal amount of and accrued and unpaid interest on the note into shares of common stock of the Issuer immediately prior to the effective time of the proposed merger transaction between the Issuer and MYnd Analytics, Inc. F2: See footnote 1. F3: Represents the outside date for completion of the proposed merger, unless extended by the parties. F4: The actual number of conversion shares may vary depending upon the closing date of the proposed merger transaction. |
| Promissory Note dated 3/6/16, as amendedSEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2019-07-31 | IndirectBy Hope International Hospice, Inc. | 1 |
Reported balance
After 2019-07-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-07-09 · Other · Acquired 1 · Balance 1 F1: The outstanding promissory note of the Issuer held by the Reporting Person was amended to provide for the automatic conversion of the outstanding principal amount of and accrued and unpaid interest on the note into shares of common stock of the Issuer immediately prior to the effective time of the proposed merger transaction between the Issuer and MYnd Analytics, Inc. F2: See footnote 1. F3: Represents the outside date for completion of the proposed merger, unless extended by the parties. F4: The actual number of conversion shares may vary depending upon the closing date of the proposed merger transaction. F5: Hope International Hospice, Inc. is a California corporation of which the Reporting Person and his wife are the sole shareholders and directors and, as such, are deemed to beneficially own the securities shown. |
Filing footnotes · ownership attribution and instrument terms
F1: The outstanding promissory note of the Issuer held by the Reporting Person was amended to provide for the automatic conversion of the outstanding principal amount of and accrued and unpaid interest on the note into shares of common stock of the Issuer immediately prior to the effective time of the proposed merger transaction between the Issuer and MYnd Analytics, Inc.
F2: See footnote 1.
F3: Represents the outside date for completion of the proposed merger, unless extended by the parties.
F4: The actual number of conversion shares may vary depending upon the closing date of the proposed merger transaction.
F5: Hope International Hospice, Inc. is a California corporation of which the Reporting Person and his wife are the sole shareholders and directors and, as such, are deemed to beneficially own the securities shown.
Emmaus Life Sciences, Inc.
Report date January 12, 2023 · Filed January 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2028-01-11 | Direct | 0 |
Reported balance
After 2023-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-12 · Grant · Acquired 7,500,000 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 07, 2022 Filed Feb 9, 2022 18:57 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,250 | $1.47 | $7,717.50 |
DisclosureSEC source: 0001209191-22-007990 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,160,656 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.43 to $1.50, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 04, 2022 Filed Feb 7, 2022 19:00 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 7,000 | $1.43 | $10,010.00 |
DisclosureSEC source: 0001209191-22-007395 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,155,406 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.32 to $1.50, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| February 03, 2022 Filed Feb 7, 2022 19:00 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 6,250 | $1.40 | $8,750.00 |
DisclosureSEC source: 0001209191-22-007395 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,148,406 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.36 to $1.44, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 21:22 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 7,000 | $1.58 | $11,060.00 |
DisclosureSEC source: 0001209191-22-000164 · doc4.xml · nonDerivative · entry 4 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,142,156 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.48 to $1.65, inclusive. F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 21:22 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 6,800 | $1.56 | $10,608.00 |
DisclosureSEC source: 0001209191-22-000164 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,135,156 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.52 to $1.65, inclusive. F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 29, 2021 Filed Jan 3, 2022 21:22 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,700 | $1.57 | $4,239.00 |
DisclosureSEC source: 0001209191-22-000164 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,128,356 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.55 to $1.60, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) and in footnotes (3) and (4) to this Form 4. F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 28, 2021 Filed Jan 3, 2022 21:22 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $1.60 | $1,600.00 |
DisclosureSEC source: 0001209191-22-000164 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,125,656 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 17:11 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,200 | $1.48 | $1,776.00 |
DisclosureSEC source: 0001209191-21-071358 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,124,656 F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 17:11 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,500 | $1.50 | $2,250.00 |
DisclosureSEC source: 0001209191-21-071358 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,123,456 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.48 to $1.54, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 22, 2021 Filed Dec 28, 2021 17:11 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,000 | $1.48 | $7,400.00 |
DisclosureSEC source: 0001209191-21-071358 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,121,956 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.41 to $1.50, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 21, 2021 Filed Dec 22, 2021 16:11 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,900 | $1.49 | $7,301.00 |
DisclosureSEC source: 0001209191-21-070895 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,116,956 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.49 to $1.50, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 20, 2021 Filed Dec 22, 2021 16:11 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,000 | $1.51 | $4,530.00 |
DisclosureSEC source: 0001209191-21-070895 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,112,056 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.51 to $1.60, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 17, 2021 Filed Dec 22, 2021 16:11 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,750 | $1.49 | $4,097.50 |
DisclosureSEC source: 0001209191-21-070895 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,109,056 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.45 to $1.50, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (3) and (4) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 21:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,000 | $1.54 | $6,160.00 |
DisclosureSEC source: 0001209191-21-070255 · doc4.xml · nonDerivative · entry 4 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,106,306 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.47 to $1.55, inclusive. F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,000 | $1.52 | $4,560.00 |
DisclosureSEC source: 0001209191-21-070255 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,102,306 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.50 to $1.53, inclusive. F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 14, 2021 Filed Dec 17, 2021 21:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,500 | $1.52 | $2,280.00 |
DisclosureSEC source: 0001209191-21-070255 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,099,306 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.47 to $1.53, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) and in footnotes (3) and (4) to this Form 4. F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 10, 2021 Filed Dec 17, 2021 21:12 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $1.57 | $1,570.00 |
DisclosureSEC source: 0001209191-21-070255 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,097,806 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 18:19 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,000 | $1.69 | $3,380.00 |
DisclosureSEC source: 0001209191-21-068959 · doc4.xml · nonDerivative · entry 4 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,096,806 F5 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.60 to $1.78, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 08, 2021 Filed Dec 10, 2021 18:19 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,200 | $1.58 | $1,896.00 |
DisclosureSEC source: 0001209191-21-068959 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,094,806 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.56 to $1.65, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 18:19 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,900 | $1.55 | $2,945.00 |
DisclosureSEC source: 0001209191-21-068959 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,093,606 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.53 to $1.56, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 06, 2021 Filed Dec 10, 2021 18:19 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,500 | $1.49 | $2,235.00 |
DisclosureSEC source: 0001209191-21-068959 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,091,706 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.40 to $1.55, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (3), (4) and (5) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 03, 2021 Filed Dec 6, 2021 21:19 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $1.55 | $1,550.00 |
DisclosureSEC source: 0001209191-21-068106 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,090,206 F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 21:19 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,400 | $1.53 | $5,202.00 |
DisclosureSEC source: 0001209191-21-068106 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,089,206 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.40 to $1.66, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 18:58 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,750 | $1.72 | $9,890.00 |
DisclosureSEC source: 0001209191-21-067479 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,085,806 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.63 to $1.92, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 18:58 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 35,600 | $1.51 | $53,756.00 |
DisclosureSEC source: 0001209191-21-067479 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,080,056 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.40 to $1.53, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| November 29, 2021 Filed Nov 30, 2021 17:47 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 16,000 | $1.45 | $23,200.00 |
DisclosureSEC source: 0001209191-21-067094 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,044,456 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.24 to $1.50, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 17:47 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 56,009 | $1.41 | $78,972.69 |
DisclosureSEC source: 0001209191-21-067094 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,028,456 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.21 to $1.50, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| November 24, 2021 Filed Nov 26, 2021 21:06 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 19,300 | $1.34 | $25,862.00 |
DisclosureSEC source: 0001209191-21-066923 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,972,447 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.35, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| November 23, 2021 Filed Nov 26, 2021 21:06 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 7,000 | $1.35 | $9,450.00 |
DisclosureSEC source: 0001209191-21-066923 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,953,147 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.33 to $1.39, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| November 22, 2021 Filed Nov 23, 2021 21:08 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 12,000 | $1.44 | $17,280.00 |
DisclosureSEC source: 0001209191-21-066398 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,946,147 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.30 to $1.49, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 21:08 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 15,000 | $1.39 | $20,850.00 |
DisclosureSEC source: 0001209191-21-066398 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,934,147 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.35 to $1.40, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| November 18, 2021 Filed Nov 19, 2021 22:07 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 13,000 | $1.28 | $16,640.00 |
DisclosureSEC source: 0001209191-21-065867 · doc4.xml · nonDerivative · entry 4 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,919,147 F5 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.21 to $1.44, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 22:07 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 13,000 | $1.29 | $16,770.00 |
DisclosureSEC source: 0001209191-21-065867 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,906,147 F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.30, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| November 16, 2021 Filed Nov 19, 2021 22:07 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 5,000 | $1.28 | $6,400.00 |
DisclosureSEC source: 0001209191-21-065867 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,893,147 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.25 to $1.29, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| November 15, 2021 Filed Nov 19, 2021 22:07 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,000 | $1.25 | $2,500.00 |
DisclosureSEC source: 0001209191-21-065867 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,888,147 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.22 to $1.29, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (3), (4) and (5) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 20, 2021 Filed Oct 22, 2021 18:41 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $1.57 | $1,570.00 |
DisclosureSEC source: 0001209191-21-061341 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,886,147 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 06, 2021 Filed Oct 7, 2021 17:40 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $1.52 | $1,520.00 |
DisclosureSEC source: 0001209191-21-059887 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,885,147 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.52 to $1.59, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 17:40 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,000 | $1.66 | $3,320.00 |
DisclosureSEC source: 0001209191-21-059887 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,884,147 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.59 to $1.68, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| September 27, 2021 Filed Sep 29, 2021 21:37 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $1.64 | $1,640.00 |
DisclosureSEC source: 0001209191-21-058088 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,882,147 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| September 24, 2021 Filed Sep 27, 2021 22:10 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $1.70 | $1,700.00 |
DisclosureSEC source: 0001209191-21-057831 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,881,147 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| September 23, 2021 Filed Sep 27, 2021 22:10 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,500 | $1.69 | $2,535.00 |
DisclosureSEC source: 0001209191-21-057831 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,880,147 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| September 22, 2021 Filed Sep 23, 2021 23:25 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,582 | $1.73 | $2,736.86 |
DisclosureSEC source: 0001209191-21-057505 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,878,647 F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 23:25 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,000 | $1.64 | $3,280.00 |
DisclosureSEC source: 0001209191-21-057505 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,877,065 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.62 to $1.73, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| September 15, 2021 Filed Sep 18, 2021 00:23 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,000 | $1.50 | $3,000.00 |
DisclosureSEC source: 0001209191-21-056769 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,875,065 F1 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:11 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,500 | $1.67 | $4,175.00 |
DisclosureSEC source: 0001209191-21-055724 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,873,065 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.59 to $1.80, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| September 08, 2021 Filed Sep 8, 2021 21:59 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,500 | $1.75 | $2,625.00 |
DisclosureSEC source: 0001209191-21-055195 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,870,565 F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 21:59 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,500 | $1.58 | $2,370.00 |
DisclosureSEC source: 0001209191-21-055195 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,869,065 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.54 to $1.60, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| September 02, 2021 Filed Sep 2, 2021 21:58 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $1.55 | $1,550.00 |
DisclosureSEC source: 0001209191-21-054540 · doc4.xml · nonDerivative · entry 3 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,867,565 F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 21:58 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,500 | $1.54 | $2,310.00 |
DisclosureSEC source: 0001209191-21-054540 · doc4.xml · nonDerivative · entry 2 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,866,565 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.53 to $1.54, inclusive. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 21:58 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 7,201 | $1.55 | $11,161.55 |
DisclosureSEC source: 0001209191-21-054540 · doc4.xml · nonDerivative · entry 1 Niihara Yutaka · CIK 0001517691 · Director · Chairman and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,865,065 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.52 to $1.55, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (3) to this Form 4. F2 · ownership.direct: The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.